MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 2.5% – What’s Next?

MiNK Therapeutics, Inc. (NASDAQ:INKT) was up 2.5% on Tuesday . The stock traded as high as $7.83 and last traded at $7.75. Approximately 2,436 shares were traded during trading, a decline of 83% from the average daily volume of 14,604 shares. The stock had previously closed at $7.56.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of MiNK Therapeutics in a research report on Tuesday, March 18th.

MiNK Therapeutics Price Performance

The firm has a market capitalization of $30.74 million, a price-to-earnings ratio of -1.99 and a beta of 0.15. The business’s 50 day moving average price is $8.76 and its 200-day moving average price is $7.84.

MiNK Therapeutics (NASDAQ:INKT) last issued its earnings results on Tuesday, March 18th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12). As a group, analysts expect that MiNK Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.